The long term use of proton pump inhibitors (PPIs), a class of drugs widely used to treat acid reflux and ulcers, may not be linked to any increased… read more.
Regular stool tests already used in NHS care, combined with dietary information, could help identify people with inflammatory bowel disease (IBD) at higher risk of relapse, a major study suggests. Researchers… read more.
Initial treatment with antibiotics is a viable option for uncomplicated acute appendicitis in adult patients, researchers reported in JAMA on January 21, 2026. “What is the long-term appendicitis… read more.
Pregnant individuals with inflammatory bowel disease (IBD) have higher levels of pro-inflammatory immune molecules, known as cytokines, in their vaginal mucosa than their healthy counterparts, according to a new… read more.
Researchers at University of California San Diego, Mass General Brigham, and their colleagues have identified specific gut bacteria and metabolic pathways that drive alcohol production in patients with… read more.
Most conversations about breast milk tend to focus on topics like nutrients, antibodies and bonding time rather than bacteria. But it turns out that human milk carries its… read more.
China has achieved significant advancements in gastroenterology and digestive endoscopy, according to the 2024 national report published in the Chinese Medical Journal. Drawing data from the National Clinical Improvement… read more.
Women are dramatically more likely than men to suffer from irritable bowel syndrome (IBS), a chronic condition causing abdominal pain, bloating, and digestive discomfort. Now, scientists at UC… read more.
Abivax SA a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases,… read more.
Eli Lilly and Company announced that the FDA approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of Omvoh (mirikizumab-mrkz) for subcutaneous use in adults with moderately to… read more.
A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and tirzepatide in patients with type 2 diabetes (T2D). The study found that… read more.
AbbVie announced the FDA approval of a supplemental new drug application (sNDA) that updates the indication statement for Rinvoq (upadacitinib) for the treatment of adults with moderately to… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
